Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).
Segovia, Diana I. , Sinicrope, Frank A. , Hardin, Aaron , Rich, Thereasa A. , Alberts, Steven R. , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3504-3504

10.1200/jco.2025.43.16_suppl.3504 Get It

3504 Background: Among patients with resected node-positive colon cancer, nearly 30% will relapse despite standard adjuvant chemotherapy. Analysis of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) may enable risk stratification for tumor recurrence and inform adjuvant treatment decisions. Methods: Postsurgical ctDNA was analyzed in patients with stage III colon carcinoma who participated in a phase 3 trial of adjuvant FOLFOX alone or combined with cetuximab (n = 3084) [NCCTG N0147]. We utilized a tissue-free epigenomic assay for ctDNA detection (Guardant Reveal) with sampling prior to start of adjuvant therapy. Among ctDNA positives, epigenomic tumor fraction (TF) was estimated and ctDNA genotyping was done with Guardant360 (panel of 739 genes). Median follow-up was 6.1 years (yr). Study endpoints included time-to-recurrence (TTR), disease-free survival (DFS) and overall survival (OS) analyzed by Kaplan–Meier method. Multivariable Cox proportional hazards models were used to assess prognostic utility of ctDNA status adjusting for confounders. Interaction between ctDNA and clinicopathological features were assessed. Results: Among 2260 patients with evaluable ctDNA data, 461 (20.4%) were ctDNA positive.Tumors were significantly associated with higher T, N stage, BRAF V600E , high grade, obstruction/perforation, and worse performance status. Positive vs negative ctDNA was significantly associated with shorter TTR (hazard ratio [HR] 4.33, 95% confidence interval [CI] 3.65-5.13, P < 0.0001), poorer DFS (HR 3.74, CI 3.18-4.39, P < 0.0001] and OS (HR 3.17, CI 2.63-3.83, P < 0.0001), adjusting for covariates and tissue MMR, KRAS and BRAF V600E . ctDNA positive vs negative patients had 3y DFS of 36.4% (95%CI 32.2-41.2%) vs 82.5% (95% CI 80.0-84.4%), respectively. Adverse prognosis was consistent across subgroups (all P < 0.05), with stronger detrimental effects for positive ctDNA in N1 (vs. N2), T1/2 (vs T3 or 4), and mismatch repair deficient tumors [interaction P = 0.0002 to 0.041). Among patients with positive ctDNA, TF in those who recurred/died within 3 yr was double of those who remained recurrence-free ( P = 0.0001). High vs. low ctDNA TF ( > vs ≤ median) further stratified TTR (HR 1.48, CI 1.17-1.88, P = 0.0011), DFS (HR 1.52, CI 1.21-1.92, P = 0.0004) and OS (HR 1.58, CI 1.21-2.07, P = 0.0009), adjusting for confounders. ctDNA positive cases, . Analyses of ctDNA detection by site of recurrence, ctDNA clearance, and genomic variant detection are ongoing. Conclusions: In the largest study evaluating tissue-free epigenomic-based MRD detection, we demonstrate a robust prognostic utility of postsurgical ctDNA. Tumor fraction provided further patient stratification and analysis is ongoing to identify a subgroup based on TF that may be unlikely to clear ctDNA despite adjuvant chemotherapy.
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
Chawla, Neal Shiv , Attia, Steven , Cranmer, Lee D., Seetharam, ­Mahesh , Bui, Nam Q. , Somaiah, Neeta , Tine, Brian Andrew Van, Chawla, Sant P. , Bui, Nam , Jones, Robin L. , Pollack, Seth M. , Cranmer, Lee D. , Pousa, Antonio Lopez , Burgess, Melissa , Chmielowski, Bartosz , Siontis, Brittany L. , Trent, Jonathan C. , Wilky, Breelyn A , Chugh, Rashmi

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 11506-11506

10.1200/jco.2025.43.16_suppl.11506 Get It

11506 Background: Catequentinib Hydrochloride (AL3818, Anlotinib, Catequentinib) is a novel, orally administered, small molecule tyrosine kinase inhibitor. There remains an unmet need for effective, well tolerated therapies for patients (pts) with advanced/ metastatic leiomyosarcoma (LMS). We performed a randomized, double blind trial of Catequentinib monotherapy versus placebo in advanced/metastatic LMS. Methods: Patients with a diagnosis of LMS requiring third or further line treatment were eligible. Catequentinib was administered in a 21-day cycle with 14 days on and 7 days off regimen. In this double blind phase 3 trial, patients were randomized 2:1 to Catequentinib or placebo, with the option of crossover to Catequentinib after confirmed Progression Disease (PD) on placebo. Progression-free survival (PFS) with Log Rank test was the primary endpoint and the trial was conducted at multiple sites in the US, UK and EU. Results: Total N = 111 patients were enrolled, and N = 110 were treated and evaluated, 74 randomized to Catequentinib (C), and 36 to placebo (P). In arms (C)/(P) median ages were 59.0/60.5 (range: 33-91) years respectively and 59/29 (79.7%/80.6%) were female. Median PFS by Blinded Independent Central Review (BICR) met the primary endpoint at 3.42 months (95% CI: 2.60, 6.83) for (C) and 1.41 months (95% CI: 1.35, 4.86) for (P) with a p-value of 0.0265 and a HR of 0.536 (95% CI: 0.307, 0.936). Median PFS for patients stratified at ≤ 3 prior lines was 4.86 months (95% CI: 2.04, 8.94) for (C) and 1.41 months (95% CI: 1.31, 4.86) for (P) with a p-value of 0.0046 and a HR of 0.386 (95% CI: 0.196, 0.760). The 6-month progression-free rate was 42.37% for (C) and 20.71% for (P). OS was 17.45 months (95% CI: 13.57, 19.32) for (C) and 16.33 months (95% CI: 11.27, NE) for crossover patients in the (P) arm. 30 (40.5%) of patients have experienced grade 3 treatment-related adverse events in the (C) arm compared to 3 (8.3%) of patients in the (P) arm. The most common TEAE for (C) vs (P) were diarrhea (50.0% vs 22.2%), stomatitis (31.1% vs 8.3%), fatigue (64.9% vs 41.7%), and hypertension (47.3% vs 19.4%). Conclusions: This phase 3 trial met the primary PFS endpoint and demonstrates superior PFS for Catequentinib vs placebo in metastatic/advanced LMS. This study confirms the acceptable benefit-risk profile of Catequentinib in LMS. Catequentinib is an effective and well tolerated treatment option for patients with LMS. Clinical trial information: NCT03016819 .
Understanding patient preferences for supplemental methods of communication of new drug approvals in breast cancer survivors.
Premji, Sarah , Halverson, Lisa, Lin, Steven Yu , Weerd, Kayla Van Der, Tarapore, Ziya, Ruddy, Kathryn J. , Haddad, Tufia C. , Halverson, Lisa, Weerd, Kayla Van Der, Tevaarwerk, Amyé , Riaz, Irbaz Bin , Goetz, Matthew P. , Giridhar, Karthik V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13551 Get It

e13551 Background: The landscape of cancer care is evolving rapidly. In 2023, there were 83 new FDA oncology approvals, and 145 interventional treatment (tx) studies opened across Mayo Clinic. We are exploring novel precision outreach approaches utilizing an LLM-integrated chatbot application to “ping” patients (pts) with specific clinical or genomic characteristics about newly available drugs or clinical trials. As novel outreach methods are considered, we surveyed a patient (pt) support group to understand communication preferences and awareness of adjuvant CDK4/6 inhibitors in tx of breast cancer (BC). Methods: On October 7, 2024, we administered a cross-sectional survey to 41 members of the Breast Cancer Support Network (BCSN) in Rochester, MN as a part of an IRB exempt quality improvement project. Leaders of the BCSN shared information to all participants, noting that the survey’s intent was to represent the pt voice and participation was voluntary. Anonymous survey data were collected with descriptive results reported. Results: 34/41 participants in the BCSN shared demographic information. The majority (83%) were > 50 years of age. 47% reported stage I BC, 12% stage II, 6% stage III, and 35% were unsure of their stage. Most participants (26/34, 76%) reported that their BC was hormone receptor positive (HR+), 2 HER-2 positive, and 6 unsure of their BC receptor status. 24/26 (92%) of pts with HR+ BC were taking or planning to start adjuvant endocrine therapy. 10/34 (29%) were aware that adjuvant CDK 4/6 inhibitors were approved. Of these 10 participants, 2 learned of it from online health resources, 6 from their clinician, 1 from social media, and 1 from a support group. The majority (66%) were unsure if they qualified for these drugs. Regarding receipt of information on new drug approvals/tx options, the highest ranked communication preference was to receive this information in person at an upcoming visit (ranked 1st by 50% of participants), followed by EHR-based message (28%), email (10%), phone call (6%), letter (4%), or an interactive chatbot (0%). Most respondents noted that communication from their healthcare provider was very important (30/37, 81%), with others stating that this was somewhat important (5/37, 14%) or neutral (2/37, 5%). Most noted that receiving information about tx options via video or visual aid before a visit would be very helpful (33/41, 80%). When asked about follow up after learning of a new drug approval, 17/32 (53%) of pts preferred an appointment, 9/32 (28%) a phone call, 3/32 (9%) a decision aid tool, and 3/32 (9%) a questionnaire to assess their understanding. Conclusions: Providing personalized, timely communication about new FDA approved tx options is important for BC survivors and critical for improving care delivery. While technological solutions could broaden awareness, this requires balancing pt preferences for direct communication with clinicians.
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Heinrich, Michael C. , Blay, Jean‐Yves , Gelderblom, Hans , George, Suzanne , Schöffski, Patrick , Mehren, Margaret von , Jones, Robin L. , Kang, Yoon‐Koo , Razak, Albiruni R. Abdul , Attia, Steven , Cesne, Axel Le , Goldstein, David , Sánchez, César , Cox, P. H. , Davis, Erika, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Bauer, Sebastian , von Mehren, Margaret , Jones, Robin L , Kang, Yoon-Koo , Razak, Albiruni Abdul , Trent, Jonathan , Attia, Steven , Le Cesne, Axel , Boye, Kjetil , Sánchez, César , Cox, Paulina , Ruiz-Soto, Rodrigo , Bauer, Sebastian , Blay, Jean-Yves , Gelderblom, Hans , Heinrich, Michael C , George, Suzanne , Zalcberg, John , Trent, Jonathan C. , Siontis, Brittany L.

Mayo Clinic

Journal of Clinical Oncology | May 23, 2025 | Volume: 43 | Issue: 20 | Pages: 2239-2244

10.1200/jco-24-02818 | PMID 40408605 Get It

In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: NCT03673501 ), adult patients with advanced gastrointestinal stromal tumor previously treated with imatinib were randomly assigned 1:1 to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). In the primary analysis, overall survival (OS) was immature. In this study, we report the final planned analysis of OS (key secondary end point), progression-free survival (PFS) on third-line therapy (second PFS; prespecified exploratory end point), and long-term safety. Final OS analysis was prespecified to occur with approximately 200 and ≥145 events in the overall and KIT exon 11 intention-to-treat (ITT) populations, respectively. As of March 15, 2023, there were 211 and 151 OS events in the overall ITT and KIT exon 11 ITT populations, respectively. Median OS was similar between second-line ripretinib and sunitinib in both populations (overall, 35.5 v 31.5 months; KIT exon 11, 35.5 v 32.8 months). Median second PFS (on third-line therapy) for the overall ITT population was similar between the ripretinib and sunitinib arms (7.7 v 7.4 months). Safety was consistent with the primary analysis. OS from this analysis was similar between arms, and second PFS suggests that receiving ripretinib did not adversely affect the PFS of third-line therapy.
Strategies for Resection of Esophageal and Gastroesophageal Junction Submucosal Tumors
Alomari, Mohammad , Knewitz, Daniel , Larios, Rocio Castillo, Julien, Jamii St., Thomas, Mathew , Elli, Enrique F. , Bowers, Steven P. , Thomas, Mathew , Castillo Larios, Rocio, Thomas, Mathew

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | May 19, 2025 | Volume: 35 | Issue: 7 | Pages: 564-569

10.1089/lap.2025.0079 | PMID 40388300 Get It

Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis
Couteur, David G. Le , Wilanksy, Susan, Lester, Steven J., Ommen, Steve R. , Geske, Jeffrey B. , Arsanjani, Reza, Ayoub, Chadi , Pereyra Pietri, Milagros, Pathangey, Girish , Le Couteur, David , Geske, Jeffrey B , Ayoub, Chadi , Awad, Kamal , Pereyra, Milagros , Farina, Juan M. , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | May 16, 2025 | Volume: 11 | Issue: 5 | Pages: 469-482

10.1093/ehjcvp/pvaf036 | PMID 40377024 Get It

Abstract Aims Significant advancements have been made in the management of obstructive hypertrophic cardiomyopathy (oHCM), yet the extent of left ventricular outflow tract (LVOT) gradient reduction achieved with commonly used pharmacological therapies [beta-blockers (BBs), calcium channel blockers (CCBs), disopyramide, and cardiac myosin inhibitors (CMIs)] relative to each other is still unclear. Methods and results PubMed and Scopus were searched up to September 2024. Clinical trials or observational studies that assessed the changes associated with BBs, CCBs, disopyramide, or CMIs in LVOT gradient at rest or with provocation in patients with oHCM were included. Mean changes in LVOT gradients were pooled as mean differences (MD) with 95% confidence intervals (CIs) in a random-effects model. Thirty-seven studies, with 44 arms and 1898 patients, were included in the analysis. At the therapeutic class level, pooled analysis showed that disopyramide was associated with the highest reduction in LVOT gradient at rest [MD: −43.5 (95% CI, −51.6 to −35.3)], followed by CMIs [MD: −34.8 (95% CI, −40.6 to −29.0)], BBs [MD: −20.7 (95% CI, −29.4 to −12.0)], and then CCBs [MD: −14.7 (95% CI, −23.3 to −6.1)], inter-action P &lt; 0.01. Within CMIs, mavacamten had a higher effect than aficamten on gradient reduction; among the included BBs, metoprolol showed the highest gradient reduction, while among CCBs, verapamil was the most effective (inter-action P &lt; 0.01). Similar results were observed for provocable LVOT gradients. Conclusion Pharmacological therapies effectively reduced LVOT gradients in oHCM patients to varying degrees, with disopyramide and CMIs showing the highest effect, followed by BBs and CCBs.
A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
Siontis, Brittany L. , Rice, John D. , Schuetze, Scott M. , Rottmann, Douglas , Angeles, Christina V. , Fox, Amanda K. , Zyczynski, Laurie E. , Hayek, Salim S. , Robinson, Steven I. , Okuno, Scott H. , Ho, Thanh P. , Hayek, Salim , Chugh, Rashmi , Siontis, Brittany L , Robinson, Steven I , Chugh, Rashmi

Mayo Clinic

Clinical Cancer Research | May 13, 2025 | Volume: 31 | Issue: 14 | Pages: 2919-2925

10.1158/1078-0432.ccr-25-0298 | PMID 40358615 Get It

Abstract Purpose: Soft-tissue sarcomas are rare malignancies with poor prognosis and limited systemic treatment options. We conducted a phase II study to assess the efficacy and safety of trabectedin and olaparib in patients with advanced disease. Patients and Methods: Patients with soft-tissue sarcoma who received ≥1 prior therapy were recruited into two cohorts. Cohort 1 included leiomyosarcoma and liposarcoma; cohort 2 included other histologies. All patients received trabectedin (1.1 mg/m2 24-hour infusion every 21 days) and olaparib (150 mg twice daily continuously). The study was conducted using a Simon minimax two-stage design with a primary endpoint of objective response (OR) rate per RECIST 1.1. Results: Twenty-nine (cohort 1, 16; cohort 2, 13) patients enrolled; one patient in cohort 2 was not evaluable. There were no confirmed ORs in cohort 1; the best response was stable disease in 12 (75%) patients and progressive disease in four (25%). Two partial responses were observed in cohort 2 (n = 12). The most common adverse events were fatigue (75%), neutropenia (75%), anemia (68%), and thrombocytopenia (68%). The median progression-free survival and overall survival for all patients were 3.5 (95% confidence interval, 3.3–8.2) and 13.2 months (95% confidence interval, 10.3–20.9), respectively. Next-generation sequencing of 17 tumors revealed multiple abnormalities, most commonly in TP53, RB1, and ATRX. Conclusions: Trabectedin plus olaparib conferred high rates of toxicity and failed to demonstrate ORs in leiomyosarcoma and liposarcoma. Preliminary evidence of clinical benefit in two patients in cohort 2 suggests potential value of either or both drugs in other sarcomas.
Disruption of Microhomology-mediated End-joining in Ewing Sarcoma
Asada, Shuhei , Tanaka, Yutaro , Abeykoon, Jithma Prasad, Tanaka, Yutaro , Mukkavalli, Sirisha , Busso, Miles Del, Thangaiah, Judith Jebastin, Van Allen, Eliezer M , Shapiro, Geoffrey I , D'Andrea, Alan , Zhu, Guangli, Abeykoon, Jithma P. , Nguyen, Huy, Hirohashi, Yuna, Iyer, Divya , Ashton, Nicholas William , Mukkavalli, Sirisha , Velazquez, Martha, Jiang, Lige, Robinson, Steven I. , Parmar, Kalindi , Gillani, Riaz , Shapiro, Geoffrey I.

Mayo Clinic

No container title available | May 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.06.651696 | PMID 40568108 Get It

SUMMARY Ewing sarcoma (EwS) is a group of bone and soft tissue cancers in children and young adults. Since EwS cells have pronounced sensitivity to radiation and chemotherapy-induced DNA damage, the role of the oncoprotein, EWS-FLI1, in DNA repair is likely. Here, we demonstrate that EWS-FLI1 causes a defect in microhomology-mediated end-joining (MMEJ) repair. EWSR1 is a splicing factor that promotes the faithful splicing of the POLQ pre-mRNA, required for the expression of POLΘ, a critical protein in the MMEJ pathway. Expression of EWS-FLI1, or loss of EWSR1, causes exon 25 skipping of the POLQ transcript, decreased POLΘ expression, impaired MMEJ, and cellular sensitivity to inhibitors of the Fanconi Anemia (FA), NHEJ, or HR pathways, through the mechanism of synthetic lethality. Knockdown of EWS-FLI1 expression restores POL0 mitotic foci and increases MMEJ activity. Inhibitors of the FA, NHEJ, or HR therefore may provide a targeted therapy for patients with EwS. Highlights - Ewing sarcoma tumors have a deficiency in POLθ expression and a corresponding loss of MMEJ activity - EWSR1 is a splicing factor that interacts with other splicing factors such as FUBP1 and KHSRP/FUBP2 to accurately splice the POLQ mRNA. - The EWS-FLI1 fusion oncoprotein, or loss of EWSR1, causes a splicing defect, leading to exon25 skipping of the POLQ pre-mRNA and loss of POLθ expression - The MMEJ deficiency of EwS cells results in cellular sensitivity to inhibitors of Fanconi Anemia, Homologous Recombination or Non-Homologous End-Joining - Exon 25 skipping of POLQ mRNA is a predictive biomarker for HR inhibitors in human cancers
Scaphocapitate Fusion and Proximal Row Carpectomy for Kienböck Disease: Comparative Analysis of Long-Term Outcomes
Emanuels, Andrew, Rames, Jess D. , Tunaboylu, Mehmet Furkan , Bodansky, David , Moran, Steven L. , Emanuels, Andrew F., Rames, Jess

Mayo Clinic

Plastic & Reconstructive Surgery | May 6, 2025 | Volume: 156 | Issue: 5 | Pages: 763-771

10.1097/prs.0000000000012178 | PMID 40327820 Get It

Background: In Kienböck disease with carpal collapse scaphocapitate fusion (SCF) and proximal row carpectomy (PRC), are mainstays of surgical treatment. This study analyzed objective and patient-reported outcomes after SCF or PRC in laborers versus nonlaborers. Methods: A retrospective cohort study of patients who underwent surgery for Kienböck disease within a single health system from 1976 to 2023 was conducted. Postoperative Disabilities of the Arm, Shoulder, and Hand (DASH) and Patient-Rated Wrist Evaluation (PRWE) scores were surveyed from the available population. Labor status, grip, ROM, and return to the operating room were collected and radiographs were analyzed. Results: Sixty-four patients underwent PRC, and 78 underwent SCF. Patients with PRC were significantly older than patients with SCF. Mean follow-up was 29 months (SD, 53 months). There was no significant difference in postoperative ROM or relative grip strength between the cohort groups. Laborers who underwent SCF demonstrated the least disability on DASH scores. There was no significant difference in postoperative DASH scores in PRC when comparing laborers versus nonlaborers. In contrast, the DASH and PRWE scores of patients who underwent SCF postoperatively varied between laborers and nonlaborers (mean ± SD, 11.1 ± 13.9 versus 30.5 ± 24.8, P = 0.005; and 17.5 ± 19.4 versus 42.3 ± 31.4, P = 0.024). Patients who underwent SCF had a greater rate of revision surgery compared with the PRC group (22 of 78 versus 6 of 64; P = 0.026). Wrist fusion rates were 19% for SCF compared with 1.6% for PRC ( P = 0.0007). Conclusions: SCF and PRC demonstrated no difference in postoperative ROM and grip based on labor status. Laborers with SCF had the least postoperative disability on DASH; however, SCF was associated with the need for additional surgical intervention and conversion to total wrist arthrodesis. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutc, III.
From Theory to Practice: Moving Toward Artificial Intelligence–powered Computer Vision Applications for Peripheral Motor Nerve Assessment of the Hand
Rames, Jess D. , Tunaboylu, Mehmet Furkan , Emanuels, Andrew, Moran, Steven L. , Tunaboylu, Mehmet F., Emanuels, Andrew F.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 1, 2025 | Volume: 13 | Issue: 4 | Pages: e6674

10.1097/gox.0000000000006674 | PMID 40196170 Get It

Summary: Computer vision has emerged as a useful technology that may prove capable of facilitating remote clinical examinations in hand surgery. This study’s primary aim is to evaluate the efficacy of computer vision for assessing peripheral motor function and range of motion of the hand for future clinic and telemedicine purposes. Five healthy volunteer subjects (10 hands total) were filmed performing three static hand examinations (“peace sign,” “hitchhiker thumb,” and “OK sign”) as well as apposition. Videos were processed using the proprietary H.AI.ND program based on the MediaPipe API (Google, v0.9.2.1), generating temporal and spatial data for joint angle analysis. The median joint angles determined for each test were compared with their manually derived counterparts to assess accuracy and reliability. The measurements were compared at a population level using Wilcoxon signed rank tests and at the individual video level using interclass correlation analyses. The artificial intelligence–generated angle outputs demonstrated a high level of reliability when compared with manually determined measurements for the 3 clinical positions included in this study. Assessment of compound appositional movement also demonstrated high reliability with time-dependent multijoint evaluation. Goniometric analysis through computer vision applications may provide an easy and reliable alternative for hand evaluation in the normal population for both static and dynamic function. Further study is warranted to evaluate this program’s potential role for diagnostic assessment in the diseased population before and after surgical investigation.